Market Newsdesk

SAN DIEGO and CALGARY, AB, Sept. 20, 2021 /PRNewswire/ — Oncolytics Biotech^® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced preclinical data demonstrating the synergistic immunotherapeutic effects of pelareorep combined with radiotherapy in a murine cancer model. The data were featured in a poster presentation at The International Conference on Immunotherapy Radiotherapy Combinations, which took place in Paris, France from September 14 – 17, 2021.

Preclinical studies presented in the poster evaluated various treatment combinations of pelareorep, ionizing radiation (radiotherapy), and anti-PD-1 therapy in mice with two bilateral tumors, each located subcutaneously (under the skin) on a different side of the body. Radiotherapy and/or pelareorep treatment was delivered locally to one tumor (denoted the primary tumor), while the second tumor (denoted the abscopal tumor) was not directly exposed to either therapy. Anti-PD-1 therapy was delivered systemically.

Results showed that in primary tumors, pelareorep monotherapy led to a numerical increase in the number of infiltrating anti-cancer CD8+ T cells, which reached statistical significance when combined with radiotherapy (a 15-fold increase compared to control). In abscopal tumors, both pelareorep monotherapy and pelareorep-radiation combination therapy led to a statistically significant increase in infiltrating anti-cancer CD8+ T cells. This effect was not seen with single-agent radiotherapy in either the primary or the abscopal tumors.

Local delivery of radiotherapy alone and the pelareorep-radiotherapy combination into primary tumors significantly improved survival compared to untreated controls. Compared to single-agent radiotherapy, the pelareorep-radiotherapy combination led to a numerical increase in survival, which reached statistical significance when anti-PD-1 therapy was added to the treatment regimen.

“The observed increases in survival and in the number of anti-cancer immune cells within both primary and abscopal tumors following treatment is indicative of the synergistic immunotherapeutic effects of the pelareorep-radiotherapy combination,” said Thomas Heineman, M.D., Ph.D., Global Head of Clinical Development and Operations at Oncolytics. “This is a compelling finding that has the potential to be broadly applicable across multiple cancer indications and warrants further study. Together with prior clinical and preclinical data, these results also highlight pelareorep’s potential as an enabling technology to enhance the efficacy of a wide range of therapies.”

A copy of the poster titled, “Combination treatment with radiotherapy and oncolytic reovirus generates CD8+ T cell infiltration in primary and abscopal tumours in an organoid model of basal-like breast cancer,” can be found on the Posters & Publications page of Oncolytics’ website (LINK).

About Oncolytics Biotech Inc.

Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype — turning “cold” tumors “hot” — through innate and adaptive immune responses to treat a variety of cancers.

Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies, as it advances towards a registration study in metastatic breast cancer. For further information, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as “forward-looking statements”). Forward-looking statements contained in this press release include statements regarding Oncolytics’ belief as to the mode of action and potential and benefits of pelareorep as a cancer therapeutic; Oncolytics’ expectations as to the purpose, design, outcomes and benefits of its current or pending clinical trials involving pelareorep; our goals, objectives and strategies; and other statements related to anticipated developments in Oncolytics’ business and technologies.  In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics’ actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics’ ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. In particular, we may be impacted by business interruptions resulting from COVID-19 coronavirus, including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption, and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how Oncolytics may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition.  Investors should consult Oncolytics’ quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

Logo – https://mma.prnewswire.com/media/1064079/Oncolytics_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/oncolytics-biotech-announces-preclinical-data-demonstrating-the-synergistic-immunotherapeutic-effects-of-pelareorep-combined-with-radiotherapy-301379841.html

SOURCE Oncolytics Biotech® Inc.

CHICAGO, Sept. 20, 2021 /PRNewswire/ — Ahead of the annual Morningstar Investment Conference, Morningstar, Inc. (Nasdaq: MORN), a leading provider of independent investment research, today announced a new analytics capability in Morningstar Direct coupling multi-faceted data sets with automated analysis to drive new insights that were previously challenging to draw out. Morningstar is accelerating the pace of interactive analytics and new research released in Morningstar Direct delivered through Notebooks, enabling investors’ access to new diversity, ownership and performance insights.

“Morningstar was built on the idea that investors need access to data and research to make better informed financial decisions. As the available data has skyrocketed, so has pressure for financial professionals to harness and analyze it to help their clients and build new investment products,” said Frannie Besztery, head of Morningstar Direct. “Existing Morningstar Notebooks have been well-received by clients, and we’re excited to create the ability for users to code, implement, and share their own Notebooks on Morningstar Direct.”

Financial professionals can use Notebooks to bring data to life in everyday research, whether it’s to help analyze managers, build portfolios, or identify new sources of risk that otherwise they wouldn’t have seen. Five individual Notebooks are currently available to users of Morningstar Direct today, and three additional datasets will be released via Notebooks by the end of 2021. The new data sets featured include: 

• Portfolio Manager Performance History, which maps the history of a portfolio manager’s career and performance data of those funds during their tenure to aid in manager selection.
• Stock Ownership Analysis, which allows users to conduct equity ownership analysis on a specific lineup of funds and obtain insight into managers who recently established or divested their position in a selected stock.
• Firm Diversity Data, which tracks asset management firms’ diversity makeup to add transparency and make it easier for asset owners to access this information and select firms that meet their diversity needs. 
• Investment Product Launches, which identifies new fund launches within a specified time period and country of sale; the data can be aggregated along several dimensions and shows detailed information about fund groups such as environmental, social, and governance (ESG) funds, exchange-traded funds, and index funds making it easier to keep track of new fund launches.
• Time Series Factor Regression Analysis, which breaks down returns into factor exposures to derive an investment’s alpha and beta exposures to enable performance analysts at asset management firms to monitor their lineup. 

Later this year, Morningstar Direct users will be able to pilot the initial release of Analytics Lab, where they will be able to develop their own custom analytics and models. Analytics Lab is a hosted development environment that seamlessly combines Morningstar’s expansive data sets and the power of Python’s data science capabilities. Financial professionals, including data scientists, financial engineers and quantitative analysts, will be able to discover, analyze and engage with Morningstar’s data ecosystem in powerful new ways.

To learn more about Morningstar Notebooks, click here. 

Morningstar Notebooks at the Morningstar Investment Conference  
Join Morningstar Sept. 22-24 for the annual Morningstar Investment Conference at McCormick Place Convention Center in Chicago, or via the digital conference experience. Morningstar will host a session, “Automating Manager Research Workflows with Analytics Lab,” in the Morningstar Theater (Room 350) featuring Morningstar Notebooks on Wednesday, Sept. 22 from 2-2:30 p.m. CT. Senior Product Manager Eileen Bingle will show attendees new ways to engage with Morningstar research, analytics, and visualizations. 

Join Timothy Strauts, head of research and content for Morningstar Direct, at the Innovation Lab on the Exhibit Hall Floor from 10-11 a.m. CT on Thursday, Sept. 23, where attendees will be able to try and experience Notebooks on their own and ask questions. 

Press Experience at the Morningstar Investment Conference 
Members of the media are invited to learn how Morningstar Direct’s Notebooks can help uncover relevant data and insights for storytelling as part of Morningstar’s press-only event, “Driven By Data: How Morningstar Resources Can Give Your Story an Edge.” The session will take place in-person and digitally on Wednesday, Sept. 22 from 2-3 p.m. CT.

Registration for the Morningstar Investment Conference is free for full-time, credentialed media, so please click here and select registration type as “Press.”  The full conference agenda is available here.

About Morningstar, Inc.

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The Company offers an extensive line of products and services for individual investors, financial advisors, asset managers and owners, retirement plan providers and sponsors, and institutional investors in the debt and private capital markets. Morningstar provides data and research insights on a wide range of investment offerings, including managed investment products, publicly listed companies, private capital markets, debt securities, and real-time global market data. Morningstar also offers investment management services through its investment advisory subsidiaries, with approximately $251 billion in assets under advisement and management as of June 30, 2021. The Company has operations in 29 countries. For more information, visit www.morningstar.com/company. Follow Morningstar on Twitter @MorningstarInc. 

©2021 Morningstar, Inc. All Rights Reserved. 

MORN-P 

Media Contact:  
Sarah Wirth, +1 312 696-6037 or [email protected]  

View original content to download multimedia:https://www.prnewswire.com/news-releases/morningstar-launches-interactive-notebooks-to-extend-access-to-data-and-analytics-visualizations-301379935.html

SOURCE Morningstar, Inc.

GERMANTOWN, Md., Sept. 20, 2021 /PRNewswire/ — Hughes Network Systems, LLC (HUGHES), an innovator in satellite and multi-transport technologies and networks for 50 years, today announced that Telespazio, a joint venture between Leonardo (67%) and Thales (33%), has selected the Hughes HeloSat™ solution for satellite communications (SATCOM) for Leonardo’s helicopters. The solution combines the Hughes HM100 gateway and the HM400 modem for SATCOM on-the-move with technical support and systems integration. Once installed on helicopters like the Leonardo SW-4 Solo optionally piloted / rotorcraft uncrewed system, HeloSat will enable connectivity through-the-rotor using the Athena-Fidus Ka-band satellite capacity via the Telespazio ground station in Fucino, Italy.

 “Building on a decades-long collaboration with Telespazio, last year we demonstrated our HeloSat technology with no packet loss through the blades of a Leonardo AW139 helicopter; now we are delivering a turnkey solution,” said Rick Lober, vice president and general manager, Hughes Defense. “With low size, weight and power, HeloSat is the only reliable, validated, wideband Beyond-Line-of-Sight SATCOM capability for helicopters to transmit uninterrupted, full-motion video in real time.”

“For the fixed-wing and rotary-wing avionics market, Telespazio has chosen to create a technological team of companies with the best solutions on the market. The approach is to solve all the issues related to an avionic satellite solution by providing: teleport services, on-board technologies, ground technologies and space capacity on satellites most suited to the proposal. When we looked for connectivity under the rotor, we turned to our strategic partner Hughes for the proof of concept, and we found an excellent solution that we can’t wait to bring to market,” said Alessandro Caranci, vice president and head of Satcom Line of Business, Telespazio. “Hughes technology, advanced waveform and in-flight experience deliver multi-megabit-per-second speeds through rotary blades without packet loss – a competitive advantage for military and commercial helicopter applications.”

At the core of the HeloSat solution, the Hughes HM System features an open standards architecture that enables resilient, cost-effective SATCOM aboard airplanes, UAVs, ships, and land-mobile platforms in addition to rotary wing aircraft. The system has been deployed for military operations worldwide, powering applications including Intelligence, Surveillance and Reconnaissance (ISR); search and rescue; emergency and disaster response; firefighting and VIP transport.

For more information about Hughes HeloSat, visit the Hughes website.  

About Telespazio

Telespazio is a joint venture between Leonardo (67%) and Thales (33%) and one of the main operators in the world in the field of satellite solutions and services. With the skills acquired in 60 years of activity in the institutional and commercial market, Telespazio has an international network of space centers and teleports (that of Fucino, one of the most important in the world for civil uses) and thanks to the participation in numerous space programs such as Galileo, EGNOS, Copernicus and COSMO-SkyMed, Telespazio places itself on the reference markets with the role of service provider and large mission integrator, offering services for the upstream, midstream and downstream segments and guaranteeing so are the objectives of space missions. www.telespazio.com

About Hughes Network Systems
Hughes Network Systems, LLC (HUGHES), an innovator in satellite and multi-transport technologies and networks for 50 years, provides broadband equipment and services; managed services featuring smart, software-defined networking; and end-to-end network operation for millions of consumers, businesses, governments and communities worldwide. The Hughes flagship Internet service, HughesNet®, connects more than 1.5 million subscribers across the Americas, and the Hughes JUPITER™ System powers Internet access for tens of millions more worldwide. Hughes supplies more than half the global satellite terminal market to leading satellite operators, in-flight service providers, mobile network operators and military customers. A managed network services provider, Hughes supports nearly 500,000 enterprise sites with its HughesON™ portfolio of wired and wireless solutions. Headquartered in Germantown, Maryland, USA, Hughes is owned by EchoStar. To learn more, visit www.hughes.com or follow @HughesConnects on Twitter and LinkedIn.

About EchoStar
EchoStar Corporation (NASDAQ: SATS) is a premier global provider of satellite communication solutions. Headquartered in Englewood, Colo., and conducting business around the globe, EchoStar is a pioneer in secure communications technologies through its Hughes Network Systems and EchoStar Satellite Services business segments. For more information, visit www.echostar.com. Follow @EchoStar on Twitter.

©2021 Hughes Network Systems, LLC, an EchoStar company. Hughes and HughesNet are registered trademarks and JUPITER is a trademark of Hughes Network Systems, LLC. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/telespazio-selects-hughes-helosat-for-airborne-satellite-communications-301379754.html

SOURCE Hughes Network Systems, LLC

NICOSIA, Cyprus and AUSTIN, Texas, Sept. 20, 2021 /PRNewswire/ — Cablenet Communication Systems Ltd, a Cyprus-based communications service provider, leverages Oracle Communications converged charging, policy and billing solutions to quickly monetize new and existing products and deliver a better customer experience.

“We needed a best-in-class solution that could scale with our rapidly growing mobile business and new product development, and deliver an unmatched experience to our customers,” said Yiannos Michaelides, Chief Information Officer at Cablenet. “Oracle Billing and Revenue Management with converged charging and policies meet all of these needs in a single, best-in-class platform. Because the platform is cloud native, we can better control deployment costs and enable continuous upgrades without disruption. The open architecture of Billing and Revenue Management also allows us to integrate other solutions without limitations as our business models and requirements evolve.”

Cablenet’s mobile business has grown fivefold in the last year and is expected to grow eightfold in the next three years. This momentum requires a highly scalable, cloud-enabled platform to support its rapidly growing customer base and the upcoming 5G rollout.

As part of its investment in next-generation networking and IT technology, Cablenet recently implemented Oracle Communications Billing and Revenue Management along with Oracle Converged Charging and Oracle Policy Management. Critical to Oracle’s selection was finding a partner that could manage both billing and charging in a single platform to help customers use voice services and download content with real-time account balance information.

“As CSPs invest in the networks of tomorrow, they need cloud native, complete solutions that power real-time customer experiences and quick time to market for innovative new products,” said Jason Rutherford, senior vice president and general manager, Oracle Communications, Applications. “Oracle’s integrated billing, converged charging, and policy solution is providing the flexible, open platform Cablenet needs to support its exponential growth and move to 5G.”

The implementation of the Oracle solution was completed by INTRASOFT International SA, a member of Oracle PartnerNetwork and a global technology solutions, products and services group with a specialized telecommunications practice. Alexandros Manos, managing director at INTRASOFT International, said, “This is an important milestone for our collaboration with Oracle and we are delighted to lead the technical implementation of these innovative Oracle solutions at Cablenet.”

To learn more about Oracle Communications industry solutions, visit: Oracle Communications LinkedIn, or join the conversation at Twitter @OracleComms.

About Oracle Communications
Oracle Communications provides integrated communications and cloud solutions for Service Providers and Enterprises to accelerate their digital transformation journey in a communications-driven world from network evolution to digital business to customer experience. www.oracle.com/communications

About Oracle
Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at oracle.com.

Trademarks
Oracle, Java, and MySQL are registered trademarks of Oracle Corporation.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cablenet-monetizes-fast-growing-mobile-business-with-oracle-301379823.html

SOURCE Oracle

BOTHELL, Wash., Sept. 20, 2021 /PRNewswire/ — BioLife Solutions, Inc. (Nasdaq: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that Joydeep Goswami, Chief Strategy and Corporate Development Officer at Illumina, will join its board of directors on October 1, 2021. In his role, he is responsible for driving planning, strategic partnerships, and acquisitions. Mr. Goswami replaces Andrew Hinson, who has retired from the board.

Mike Rice, BioLife Chairman and CEO, commented, “We are thrilled with the addition of Joydeep to our board of directors.  He brings a wealth of relevant life sciences tools experience and domain expertise to our board. We look forward to his contributions as we continue to scale the business to create more shareholder value.”

Mr. Goswami remarked, “It’s my absolute pleasure to join the board of BioLife. I’ve known CEO Mike Rice, CFO Rod de Greef and CSO Aby J. Mathew, PhD, for fifteen years and have watched their execution in building BioLife into a premier and trusted brand and supplier of disruptive tools to the cell and gene therapy space.”

Prior to Illumina, Mr. Goswami served as the President of Thermo Fisher Scientific’s Clinical Next-Generation Sequencing (NGS) and Oncology business unit, where he oversaw efforts that drove the adoption of NGS in clinical oncology, research and reproductive health. Goswami has held senior leadership roles across the pharma/biotech, diagnostics and research tool continuum, previously serving at companies such as Life Technologies and Invitrogen, in addition to Thermo Fisher Scientific. He has led teams across various functions, including sales, marketing, R&D and other support functions. Mr. Goswami served as President, Asia Pacific and Japan while at Thermo Fisher Scientific and created the Stem Cells and Regenerative Medicine Business Unit at Invitrogen. Additionally, he spent five years at McKinsey, where he specialized in strategy for pharmaceutical, medical technology and technology companies.

Mr. Goswami holds his MS, PhD in Chemical Engineering, and MBA from MIT and a Bachelor’s degree in Chemical Engineering from the Indian Institute of Technology.

Rice continued, “Our team members and board of directors would like to thank Andy Hinson for his many years of service to BioLife. His contributions in advising management on the cell and gene therapy space and customers’ use of our products were invaluable.”

About BioLife Solutions

BioLife Solutions is a leading supplier of cell and gene therapy bioproduction products and services. Our portfolio includes our proprietary CryoStor^® freeze media and HypoThermosol^® shipping and storage media, ThawSTAR^® family of automated, water-free thawing products, evo^® cold chain management system, Custom Biogenic Systems^® high-capacity cryogenic freezers, Stirling Ultracold ULT freezers, and SciSafe biologic materials storage. For more information, please visit www.biolifesolutions.com, www.savsu.com, www.custombiogenics.com, www.scisafe.com, www.stirlingultracold.com, www.sextonbio.com and follow BioLife on Twitter.

Contacts:

At the Company

Roderick de Greef

Chief Financial Officer
(425) 686-6002
[email protected]

Investors
LHA Investor Relations
Jody Cain
(310) 691-7100
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/biolife-solutions-appoints-joydeep-goswami-mba-phd-to-board-of-directors-301379980.html

SOURCE BioLife Solutions, Inc.

DALLAS, Sept. 20, 2021 /PRNewswire/ — NexPoint Real Estate Finance, Inc. (NYSE: NREF) (“NREF”) announced today that its board of directors has declared a dividend of $0.53125 per share of NREF’s 8.50% Series A Cumulative Redeemable Preferred Stock, payable on October 25, 2021 to stockholders of record on October 15, 2021. 

About NexPoint Real Estate Finance, Inc.

NexPoint Real Estate Finance, Inc., is a publicly traded REIT, with its shares listed on the New York Stock Exchange under the symbol “NREF” primarily focused on originating, structuring and investing in first mortgage loans, mezzanine loans, preferred equity and alternative structured financings in commercial real estate properties, as well as multifamily commercial mortgage backed securities.  More information about NREF is available at http://nref.nexpoint.com.

Contact: 

Jackie Graham

Investor Relations
[email protected]
Media inquiries: [email protected]

View original content:https://www.prnewswire.com/news-releases/nexpoint-real-estate-finance-inc-announces-preferred-stock-dividend-301379941.html

SOURCE NexPoint Real Estate Finance, Inc.

SALT LAKE CITY, Sept. 20, 2021 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Cantor Fitzgerald Virtual Global Healthcare Conference. The conference will be held virtually. Presentation details are below.

Cantor Fitzgerald Virtual Global Healthcare Conference September 27-30, 2021

Presentation time:       September 30, 2021 starting at 1:20 p.m. EST
Webcast link:          https://wsw.com/webcast/cantor12/lpcn/2081730

The webcast of this presentation will also be available on Lipocine’s corporate website under “Events and Presentations” in the Investors section or using the webcast link above.  The webcast will be available on Lipocine’s website for 90 days. 

About Lipocine
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine’s clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148, LPCN 1107 and LPCN 1154. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, has received tentative approval from the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. LPCN 1144, an oral prodrug of bioidentical testosterone, recently completed a Phase 2 clinical study demonstrating the potential utility in the treatment of non-cirrhotic NASH.   TLANDO XR, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing. In a phase 2 clinical evaluation when administered as once daily or twice daily TLANDO XR met the typical primary and secondary end points. LPCN 1148 is an oral prodrug of bioidentical testosterone targeted for the treatment of cirrhosis. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. LPCN 1154 is an oral neuro-steroid targeted for the treatment of post-partum depression.  For more information, please visit www.lipocine.com.   

View original content to download multimedia:https://www.prnewswire.com/news-releases/lipocine-to-present-at-the-cantor-fitzgerald-virtual-global-healthcare-conference-301379043.html

SOURCE Lipocine Inc.

NEW YORK, Sept. 20, 2021 /PRNewswire/ — Saratoga Investment Corp (“Saratoga“) (NYSE:SAR) (“Saratoga Investment” or “the Company”), a business development company (“BDC”), was selected as the recipient of the 2021 Best U.S. Boutique CLO Manager by Creditflux, a London-based global publication and leading information source for the global market of credit funds and CLOs. The award is given to one CLO manager each year with four or fewer outstanding CLOs.  It is the third consecutive year that Saratoga has been nominated for Creditflux Best U.S. Boutique CLO Manager.

Creditflux’s Credit Symposium and Manager Awards took place on September 8, 2021. The 12th Creditflux Manager Awards are fully quantitative performance-based awards for the global CLO and credit fund management industry. Each year, they reward the best performance throughout the world over the previous 12 months. Awards were given to managers of private credit funds, high yield funds, CLOs and hedge funds from across the industry and the globe, representing a wide range of strategies and styles. Awards are objectively calculated based on several criteria including a combination of annualized cash distributions, debt compliance coverage, weighted average price and spread, average portfolio ratings and CCC balances, standard deviation on cash distributions, and annualized IRRs.

Saratoga has managed a collateralized loan obligation (“CLO”) fund, currently $650 million in size, since Saratoga’s inception. The CLO has completed four investment period extensions or “resets” during that period, and has never been out of compliance with its debt compliance ratios under Saratoga management. The CLO has distributed $73 million in cash distributions and $27 million in management fees to its shareholders since inception.   

“We are extremely honored to be recognized by Creditflux as the Best US Boutique CLO Manager,” said Christian Oberbeck, Chairman and CEO of Saratoga. “Our award selection is indicative of the depth and breadth of the Saratoga credit platform. For over 11 years we have provided strong, consistent financial performance for our investors and shareholders. We are pleased to be selected for this prestigious award which was based purely on objective criteria.” 

Tom Inglesby, CLO portfolio manager, added “On behalf of our Saratoga shareholders, we appreciate the recognition of this award, which reflects our strong record of credit selection, cash distributions and debt compliance, as well as our ability to complete four separate investment period resets.” 

About Saratoga Investment 

Saratoga Investment is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests primarily in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors.  Saratoga Investment’s objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments. Saratoga Investment has elected to be regulated as a business development company under the Investment Company Act of 1940 and is externally-managed by Saratoga Investment Advisors, LLC, an SEC-registered investment advisor focusing on credit-driven strategies. Saratoga Investment owns two SBIC-licensed subsidiaries and manages a $650 million collateralized loan obligation (“CLO”) fund. It also owns 52% of the Class F and 100% of the subordinated notes of the CLO. The Company’s diverse funding sources, combined with a permanent capital base, enable Saratoga Investment to provide a broad range of financing solutions.

View original content:https://www.prnewswire.com/news-releases/creditflux-selects-saratoga-investment-corp-as-the-2021-best-us-boutique-clo-manager-301379973.html

SOURCE Saratoga Investment Corp.

STAMFORD, Conn., Sept. 20, 2021 /PRNewswire/ — TN Capital Advisors (“True North”), a mergers & acquisitions advisory boutique, today announced that Tony Allott will join as Senior Advisor.

Allott, who serves as Chairman of the Board at Silgan Holdings Inc. (NASDAQ: SLGN), and was the company’s Chief Executive Officer until September 1, has had a distinguished career over 16 years managing a global manufacturer of sustainable rigid packaging and dispensing solutions. During his time at Silgan Holdings, he oversaw the completion of more than 20 acquisitions, significantly diversifying its businesses and becoming a global market leader.

During Allott’s tenure, Silgan executed a strategy of diversifying its geographic footprint and expanding its product range and growth opportunities. His experience in merging teams, working with Boards and investors, integrating acquisitions and witnessing both successes and failures, provides him with a unique operational perspective from which he can provide counsel to management teams not only in the strategic planning and execution phases of the transaction process, but also in the integration process.

Pat McDonough, Founder of True North, said, “We are thrilled to welcome Tony aboard. He offers a unique perspective on the challenges and opportunities of major business transactions, which will serve as a valuable resource to our corporate clients. His addition significantly strengthens True North’s mission of providing objective, seasoned, and differentiated advice for any and all strategic considerations that are important to the directors and officers we serve.”

Mr. Allott commented, “I have always been impressed with the level of experienced advice and support provided by True North, and believe this combination with practical operational and implementation capability will make our client offering truly unique.”

Prior Silgan, Mr. Allott was Senior Vice President and Chief Financial Officer of Applied Extrusion Technologies, Inc., or AET, a manufacturer of flexible packaging. He also served as Corporate Controller and Director of Financial Reporting of Ground Round Restaurants. He began his professional career as a certified public accountant with Deloitte.

About True North

True North benefits from the 30+ years of mergers and acquisitions experiences of its founder, Pat McDonough, and the operational and transaction integration experience of senior advisor Tony Allott.  The firm represents select corporate issuer firms with advice on all strategic matters, including acquisitions, mergers, sales, divestitures, spin-offs, restructurings, and recapitalizations. True North was founded on providing clients best in class creative and innovative thought around transaction ideas and transaction structures, outstanding analytics and presentation of those complicated analytics in a clear way. For additional information, please visit https://www.tncapitaladvisors.com. 

Media Contacts:

Nick Rust

Prosek Partners
(646) 818-9252
[email protected]

View original content:https://www.prnewswire.com/news-releases/true-north-capital-advisors-welcomes-tony-allott-as-senior-advisor-301379060.html

SOURCE TN Capital Advisors

PLANO, Texas, Sept. 20, 2021 /PRNewswire/ — Viaero Wireless, a regional telecommunications company that has served parts of the Midwest and western U.S. for more than 30 years, has selected Ericsson to replace and upgrade its existing LTE equipment to end-to-end 5G-ready products and solutions. With this modernization, Viaero will be able to offer upgraded mobility and broadband services, which will result in an improved customer experience for their subscribers.

“We needed a partner that could step up and provide a turn-key solution,” said Frank DiRico, CEO and Founder of Viaero. “The key to our success is providing the best possible service to our customers. In addition to Ericsson’s industry-leading products and solutions, we felt that Ericsson had the best team to make this project successful when looking at different technology options.”

Headquartered in Fort Morgan, Colorado, Viaero is one of the largest regional carriers in the country, covering parts of Colorado, Nebraska, Wyoming, and Kansas. Under the agreement, Ericsson will replace existing core, radio access network (RAN), microwave and router equipment across more than 900 LTE sites in Viaero’s network.

Ericsson will provide its industry-leading cloud-native core https://www.ericsson.com/en/core-network/5g-core/demos, as well its innovative best-in-class RAN portfolio, microwave, and transport solutions. This robust portfolio of products and solutions will allow Viaero to expand its connectivity footprint, reach more customers, and continue delivering high-speed internet to rural America.

“With their large footprint across the heart of the U.S., Viaero recognized the need for reliable 5G-ready networks to bring connectivity and digitization to businesses and consumers,” said Niklas Heuveldop, President and Head of Ericsson North America. “We’re proud they’ve chosen Ericsson for this important work that will help bridge the digital divide and bring fast, reliable broadband service for all.”

As a trusted partner to all of the major service providers and many regional carriers across the country, Ericsson is committed to supporting the market through the most advanced technology and services.

NOTES TO EDITORS
Ericsson 5G
Ericsson RAN
Ericsson Radio System (portfolio)
Ericsson Mobile Transport
Ericsson Cloud Packet Core
Ericsson Cloud IMS
Ericsson MINI-LINK 
Ericsson Router 6000

For media kits, backgrounders and high-resolution photos, please visit www.ericsson.com/press

FOLLOW US:
www.twitter.com/ericsson
www.facebook.com/ericsson
www.linkedin.com/company/ericsson
www.youtube.com/ericsson
Subscribe to Ericsson press releases here.

www.viaero.com

https://www.facebook.com/viaero

https://twitter.com/viaero

https://www.linkedin.com/company/viaero-wireless

https://www.youtube.com/channel/UCBzh0jSFvqPhk5eQtJDR5Ag

MORE INFORMATION AT:
News Center

MEDIA RELATIONS:
Jannie Tong for Ericsson
[email protected]
+1 214-415-0815

Lori Searls for Viaero Wireless
Director of Marketing
[email protected]   

ABOUT ERICSSON
Ericsson enables communications service providers to capture the full value of connectivity. The company’s portfolio spans Networks, Digital Services, Managed Services, and Emerging Business and is designed to help our customers go digital, increase efficiency and find new revenue streams. Ericsson’s investments in innovation have delivered the benefits of telephony and mobile broadband to billions of people around the world. The Ericsson stock is listed on Nasdaq Stockholm and on Nasdaq New York. www.ericsson.com

ABOUT VIAERO WIRELESS
We believe small communities deserve the same dependable cellular and internet services that city dwellers enjoy. We have been connecting communities in Colorado, Kansas, Nebraska, and Wyoming for 30 years. We provide broadband internet and wireless services to help keep families, businesses, and classrooms connected. Based in Fort Morgan, Colorado, we hire locally across the markets we serve. We are honored to be a preferred provider of communication services. www.viaero.com

View original content:https://www.prnewswire.com/news-releases/viaero-wireless-one-of-us-largest-regional-carriers-selects-ericsson-to-upgrade-network-equipment-301379252.html

SOURCE Ericsson